Oncology: Mutation testing for lung cancer completed prior to start of targeted therapy - ICD-10-CM Quality Payment Program Measure

Quality Measure Description High Priority Submission Methods
Oncology: Mutation testing for lung cancer completed prior to start of targeted therapyProportion of stage 4 NSCLC patients tested for actionable biomarkers, including EGFR, BRAF mutation; ROS1, ALK rearrangement; PD-L1 expression, and received targeted therapy or chemotherapy based on biomarker results.YESRegistry

Linked ICD-10 Codes

The following ICD-10-CM codes are linked to the quality measure oncology: mutation testing for lung cancer completed prior to start of targeted therapy when used as part of a patient's medical record. This Quality Measure is part of Medicare's Quality Payment Program (QPP).

ICD CodeDescriptionCategory

View All Quality Payment Program Measures